 SOUTH SAN FRANCISCO, Calif., May 12, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer will discuss progress on its AlloCAR T platform during a virtual CD19 Forum on May 19, 2021 at 2:30 PM Pacific Time5:30 PM Eastern Time. The Forum will include results from Phase 1 ALPHA ALLO-501 and ALPHA2 ALLO-501A trials in relapsedrefractory non-Hodgkin lymphoma, developed in collaboration with Servier. The Company will also share safety, pharmacokinetic PK and pharmacodynamic PD data from ALLO-647, a component of its differentiated lymphodepletion regimen. 